Format

Send to

Choose Destination
Blood. 2019 Apr 9. pii: blood.2019852368. doi: 10.1182/blood.2019852368. [Epub ahead of print]

Acalabrutinib for Mantle Cell Lymphoma.

Author information

1
Department of Hematology, Mayo Clinic, United States witzig.thomas@mayo.edu.
2
Division of Hematology, Mayo Clinic, United States.

Abstract

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma (NHL) characterized by the overexpression of cyclin D1. MCL patients typically live years but experience multiple relapses. Acalabrutinib (Acala) is a novel second generation oral Bruton's tyrosine kinase (BTK) inhibitor approved by the US FDA for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

PMID:
30967367
DOI:
10.1182/blood.2019852368

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center